The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies…
Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected to Present 6-Month data in 2026 at a…
New proprietary research from Oriflame redefines beauty as a powerful driver of wellbeing STOCKHOLM, Oct. 8, 2025 /PRNewswire/ -- Global…
BERLIN, Oct. 7, 2025 /PRNewswire/ -- New research presented today at UEG Week 2025 shows that microplastics – plastic particles smaller…
October 05, 2025 09:00 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…
HONG KONG, Oct. 2, 2025 /PRNewswire/ -- A landmark study conducted by The Hong Kong University of Science and Technology…
19th year of survey reveals cybersecurity remains top concern as workforce-related risks fall on global risk agenda DUBLIN, Oct. 1,…
New findings reveal critical microbial drivers, ethnic variations, and new pathways for personalized scalp care NEW YORK, Sept. 29, 2025…
As part of New York Climate Week, LanzaJet's CEO addressed the President of the Republic of Kazakhstan and met with…
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…